---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000036"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:48:10.386007+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbbVie updates 2023 EPS guidance to include $66M acquired IPR&D expense

## Summary
- Q3 2023 acquired IPR&D & milestones expense of $66M pre-tax; reduces diluted EPS by $0.04.
- Updated Q3 2023 adjusted diluted EPS guidance: $2.76 - $2.86 (previously $2.80 - $2.90).
- Full-year 2023 adjusted diluted EPS guidance: $10.86 - $11.06 (previously $10.90 - $11.10).
- Prior guidance excluded Q3 2023 IPR&D expense; company does not forecast such expenses.

## SEC filing metadata
- accession: 0001551152-23-000036
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000036/0001551152-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000036/abbv-20231004.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000036
- JSON: https://secwatch.observer/filing/0001551152-23-000036.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000036.txt

## Key facts
- Earnings Releases
  AbbVie Inc. updated its the third quarter of 2023 guidance (reaffirmed).
  - Period: the third quarter of 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2023 are expected to include acquired IPR&D and milestones expense of $66 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2023 have not been finalized and are subject to our financial statement closing procedures.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000036/0001551152-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.